Immunotherapy For Type 1 Diabetes Deemed Safe In First U.S. Trial
In the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes, patients experienced no serious adverse reactions after receiving infusions of as many as 2.6 billion cells that had been specially selected to protect the body’s ability to produce insulin.